- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
First-time generic approvals (October 2006)
Trimipramine capsules, 25, 50, and 100 mg (equiv to Surmontil capsules)
Trimipramine capsules, 25, 50, and 100 mg (equiv to Surmontil capsules)
AMIDE PHARMACEUTICAL
Venlafaxine tablets, 25, 37.5, 50, 75, and 100 mg (equiv to Effexor tablets)
Ciprofloxacin injection, 10 mg/mL, packaged in 200 mg/20 mL and 400 mg/40 mL single-use vials (equiv to Cipro IV injection)
ABRAXIS, SICOR, HOSPIRA, BEDFORD
Ciprofloxacin injection, 10 mg/mL, packaged in a 1,200 mg/120 mL single-use vial (pharmacy bulk package) (equiv to Cipro IV injection)
BEDFORD
Lamotrigine tablets 25, 100, 150, and 200 mg (equiv to Lamictal tablets)
TEVA
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
